Table 2 Univariable and stepwise multivariable regression analysis for CEA of the training cohort.

OR (95%CI)

P value

OR (95%CI)

P value

Gender

Male

38(63.3)

1

Female

22(36.7)

1.07 (0.55–2.06)

0.848

mLN

Negative

27(45.0)

1

Positive

33(55.0)

3.49 (1.79–6.80)

< 0.001

2.29 (0.74–7.14)

0.152

mEMVI

Negative

23 (38.3%)

1

Positive

37 (61.7%)

6.66 (3.29–13.50)

< 0.001

2.30 (0.74–7.10)

0.149

TBC

pTBC

17 (28.3%)

1

iTBC

43 (71.7%)

6.89 (3.41–13.94)

< 0.001

2.29 (0.74–7.14)

0.152

Nodular protrusion or mLN on the posterior wall

No

39(65.0)

1

Yes

21(35.0)

4.31 (1.93–9.60)

< 0.001

Synchronous metastasis

No

51 (85%)

1

Yes

9 (15%)

2.55 (0.90–7.23)

0.079

Tumor location

Lower

16 (26.7%)

1

Mid-upper

44 (73.3%)

1.26 (0.63–2.55)

0.513

Peritoneal invasion

Negative

48 (80%)

1

Positive

12 (20%)

4.25 (1.50–12.00)

0.006

pEMVI

Negative

35 (58.3%)

1

Positive

25 (41.7%)

2.37 (1.20–4.68)

0.013

Circumferential extent

≤ 1/3

1 (1.7%)

1

1/3 − 2/3

13 (21.7%)

3.18(0.37–26.94)

0.289

≥ 2/3

46 (76.7%)

9.73(1.21–78.23)

0.032

pLN

Negative

39 (65%)

1

Positive

21 (35%)

1.62 (0.81–3.21)

0.171

Degree of differentiation

High

2 (3.3%)

1

Moderate-poor

58 (96.7%)

2.01(0.40–10.00)

0.394

Growth pattern

Localized mass

15 (25%)

1

Annular infiltration

45 (75%)

3.75(1.87–7.53)

< 0.001

2.36 (1.06–5.25)

0.036

Subtypes of adenocarcinoma

Ulcerative

49 (81.7%)

1

Polypoid

7 (11.7%)

0.38 (0.15–0.93)

0.035

Mucinous

4 (6.7%)

3.14 (0.55–17.81)

0.196

MED (mm)

7.9 (3.1–11.4)

1.25 (1.15–1.36)

< 0.001

1.19 (1.03–1.38)

0.016

Tumor length (cm)

5.8 (4.5–7.0)

1.22(1.05–1.41)

0.009

Age (y)

63.7 ± 10.7

1.00(0.97–1.03)

0.895